Preventing extracellular matrix degradation

Highly Specific Therapeutics That Improve Treatment Outcomes Without Toxicity

The degradation of the extracellular matrix is a key contributor to cancer and arthritis pathogenesis, but to date candidate drugs that stop the process  have been limited in their use due to toxicity profiles. 

Albatroz has exclusive rights to Calnexin, a highly specific and novel target that is critical to extracellular matrix degradation. This provides the platform to develop a range of first-in-class therapeutic antibodies to safely and effectively treat patients.

Blocking Cancerous Tumor Growth, Metastasis and Recurrence

Cancer that has metastasized, spreading to other parts of the body, is notoriously difficult to treat and accounts for most cancer deaths.

Our objective is to prevent highly aggressive cancers, such as pancreatic, lung , and liver cancers from growing and spreading to other organs. The company has developed first-in-class therapeutic antibodies that block Calnexin, a novel tumor surface protein, that is critical to the tumor’s ability to degrade the extracellular matrix, a physical barrier preventing the growth of solid tumors in most organs of the body.

Because tumors need to destroy this barrier to create space for their growth and proliferation to other organs in the body, these antibodies stop tumor growth and help prevent tumor metastasis to other organs without the toxicity associated with other treatments.

Our antibodies have demonstrated potency against tumor models with no detectable toxicity in vivo.

Preventing the Destruction of Arthritic Joint Cartilage

Today, there is no cure for arthritis. Albatroz is committed to significantly Improving the mobility of people by preventing the destruction of the arthritic joint cartilage  – without toxicity.

In many forms of common types of arthritis, including osteoarthritis and rheumatoid arthritis, the degradation of the extracellular matrix causes the synovial membrane to degrade in arthritic joints.

Albatroz is developing first-in-class therapeutic antibodies that block the destruction of cartilage in the joints, thereby actually preventing the progression of arthritis and allowing the joint to heal.

Pipeline

Our R&D Priorities and Assets

Indication

Target

Mode of Action

Discovery

Preclinical Evaluation

IND Enabling

Phase 1
(Basket Trial of Lead Indications)

Solid Tumors

(Adjuvant)

Target

Mode of Action

Calnexin

Neutralising

Discovery

Preclinical Evaluation

IND Enabling

Phase 1
(Basket Trial of Lead Indications)

ALB-01
ALB-01

Solid Tumors

(Tumor reduction)

Target

Mode of Action

Calnexin

ADC

Discovery

Preclinical Evaluation

IND Enabling

Phase 1
(Basket Trial of Lead Indications)

ALB-02
ALB-02

Rheumatoid Arthritis

Target

Mode of Action

Calnexin

Neutralising

Discovery

Preclinical Evaluation

IND Enabling

Phase 1
(Basket Trial of Lead Indications)

ALB-03
ALB-03